LOWER: Lomitapide Observational Worldwide Evaluation Registry
Research payments
$191,923
Through program year 2023, $191,923 in research payments was reported against LOWER: Lomitapide Observational Worldwide Evaluation Registry, across 340 payments, paid by Amryt Pharma Holdings Ltd.
- Paid by
- Amryt Pharma Holdings Ltd
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $24,570 | 34 |
| 2022 | Research | $63,093 | 115 |
| 2021 | Research | $45,010 | 83 |
| 2020 | Research | $59,250 | 108 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Peter Fail Houma, LA Named on 24 payments
- Dharmesh Patel Memphis, TN Named on 13 payments
- David Murdock Wausau, WI Named on 12 payments
- Peter McCullough Dallas, TX Named on 12 payments
- Seth Baum Boca Raton, FL Named on 9 payments
- Janice McAlister Fayetteville, GA Named on 8 payments
- James Trippi Indianapolis, IN Named on 8 payments
- David Whellan Philadelphia, PA Named on 7 payments
- David Schneider Burlington, VT Named on 7 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.